Physician profile
William G Cruce
NPI 1255506101
$5,977.18
in general payments reported to CMS, 2019-2025
40 companies · $191 in 2025
The $191 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,410 · 2020: $146 · 2021: $479 · 2022: $2,312 · 2023: $300 · 2024: $139 · 2025: $191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $629.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $629.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orthofix Medical, INC. | $1,773.65 | 2019-2022 | |
| Titan Surgical Group, LLC | $1,200.00 | 2022 | |
| Integra Lifesciences Corporation | $1,117.54 | 2019-2021 | |
| Organogenesis INC. | $263.62 | 2020-2024 | Puraply |
| Bioventus LLC | $142.89 | 2022 | |
| Axogen | $123.38 | 2019 | |
| Abbvie INC. | $121.39 | 2021-2024 | |
| Treace Medical Concepts, INC. | $116.32 | 2021 | |
| Smith+Nephew, INC. | $104.17 | 2019-2021 | |
| Amgen INC. | $95.17 | 2021-2023 | Evenity, Prolia |
| Kerecis Limited | $86.48 | 2021-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Lilly USA, LLC | $70.53 | 2022-2023 | Mounjaro |
| Musculoskeletal Transplant Foundation INC. | $66.56 | 2021 | |
| Lifenet Health | $58.96 | 2023-2025 | Theragenesis Wound Matrix |
| Surgenex LLC | $52.03 | 2025 | Surgraft, Ardeograft, Pellograft |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Cruce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.